Ken Griffin Denali Therapeutics Inc. Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 14,400 shares of DNLI stock, worth $309,456. This represents 0.0% of its overall portfolio holdings.

Number of Shares

14,400

Previous 15,500 7.1%

Holding current value

$309,456

Previous $359,000 16.71%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$20.96 - $31.05 $9.25 Million - $13.7 Million	-441,418 Reduced 36.22%	777,280 $22.6 Million
Q2 2024 Aug 14, 2024	SELL	$14.96 - $23.22 $2.19 Million - $3.4 Million	-146,330 Reduced 10.72%	1,218,698 $28.3 Million
Q1 2024 May 15, 2024	BUY	$15.83 - $23.35 $20.5 Million - $30.3 Million	1,296,918 Added 1904.15%	1,365,028 $28 Million
Q4 2023 Feb 14, 2024	BUY	$16.2 - $23.18 $100,521 - $143,831	6,205 Added 10.02%	68,110 $1.46 Million
Q3 2023 Nov 14, 2023	BUY	$20.63 - $30.17 $119,695 - $175,046	5,802 Added 10.34%	61,905 $1.28 Million
Q2 2023 Aug 14, 2023	SELL	$23.37 - $32.96 $30.8 Million - $43.4 Million	-1,318,222 Reduced 95.92%	56,103 $1.66 Million
Q1 2023 May 15, 2023	BUY	$21.91 - $32.67 $29.4 Million - $43.8 Million	1,339,712 Added 3870.55%	1,374,325 $31.7 Million
Q4 2022 Feb 14, 2023	SELL	$26.28 - $33.92 $760,122 - $981,102	-28,924 Reduced 45.52%	34,613 $962,000
Q3 2022 Nov 14, 2022	SELL	$25.97 - $38.53 $6.3 Million - $9.34 Million	-242,465 Reduced 79.24%	63,537 $1.95 Million
Q2 2022 Aug 15, 2022	SELL	$20.88 - $35.19 $9.3 Million - $15.7 Million	-445,601 Reduced 59.29%	306,002 $9.01 Million
Q1 2022 May 16, 2022	BUY	$29.0 - $47.27 $7.71 Million - $12.6 Million	265,920 Added 54.75%	751,603 $24.2 Million
Q4 2021 Feb 14, 2022	BUY	$42.59 - $55.02 $18 Million - $23.3 Million	422,672 Added 670.79%	485,683 $21.7 Million
Q3 2021 Nov 15, 2021	SELL	$48.48 - $78.23 $8.62 Million - $13.9 Million	-177,773 Reduced 73.83%	63,011 $3.18 Million
Q1 2021 May 17, 2021	BUY	$53.8 - $81.53 $12.7 Million - $19.2 Million	235,671 Added 4609.25%	240,784 $13.7 Million
Q4 2020 Feb 16, 2021	SELL	$36.89 - $93.56 $7.86 Million - $19.9 Million	-213,024 Reduced 97.66%	5,113 $428,000
Q3 2020 Nov 16, 2020	BUY	$23.13 - $38.84 $2.49 Million - $4.18 Million	107,572 Added 97.29%	218,137 $7.82 Million
Q2 2020 Aug 14, 2020	BUY	$16.01 - $28.82 $611,790 - $1.1 Million	38,213 Added 52.82%	110,565 $2.67 Million
Q1 2020 May 15, 2020	BUY	$14.2 - $27.98 $266,477 - $525,072	18,766 Added 35.02%	72,352 $1.27 Million
Q4 2019 Feb 14, 2020	SELL	$14.4 - $19.99 $501,451 - $696,111	-34,823 Reduced 39.39%	53,586 $933,000
Q3 2019 Nov 14, 2019	SELL	$15.32 - $21.92 $1.63 Million - $2.33 Million	-106,467 Reduced 54.63%	88,409 $1.35 Million
Q2 2019 Aug 14, 2019	BUY	$18.5 - $28.14 $3.09 Million - $4.7 Million	167,111 Added 601.88%	194,876 $4.05 Million
Q1 2019 May 15, 2019	SELL	$17.99 - $24.65 $389,591 - $533,820	-21,656 Reduced 43.82%	27,765 $0
Q2 2018 Aug 10, 2018	BUY	$15.25 - $21.02 $753,670 - $1.04 Million	49,421 New	49,421 $0

Others Institutions Holding DNLI

# of Institutions

227

Shares Held

119M

Call Options Held

60.6K

Put Options Held

48.4K

View Full List

About Denali Therapeutics Inc.

Ticker DNLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 134,174,000
Market Cap $2.88B
Description
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...

More about DNLI

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account